1. Introduction {#sec1}
===============

Cardiometabolic disorders place significant burdens on the healthcare system worldwide \[[@B1]\]. Their prevalence has been rising over the past decades due to an aging population and an increasing level of obesity \[[@B2], [@B3]\]. Diabetes mellitus is an endocrine disorder characterized by reduced insulin production (type 1) or increased insulin resistance (type 2), leading to hyperglycaemia. There is increasing evidence that diabetes increases the risk of cardiac arrhythmias. This involves abnormalities in action potential conduction or repolarization (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), due to a complex interplay of ion channel abnormalities and electrophysiological remodelling superimposed upon a cardiomyopathic process together with autonomic dysregulation ([Figure 3](#fig3){ref-type="fig"}). Some of these findings are derived from experiments performed in animal models, which have been proven extremely useful for dissecting the molecular mechanisms responsible for arrhythmic phenotypes \[[@B4]\]. In this review, the pathophysiology underlying cardiac arrhythmias in diabetes mellitus is explored in detail, followed by an outline of potential therapeutic targets for reducing arrhythmic risk and sudden death in diabetic patients.

2. Arrhythmogenic Mechanisms in Diabetes Mellitus {#sec2}
=================================================

The common arrhythmogenic mechanism is reentry, which occurs when an action potential fails to extinguish itself and reactivates a region that has recovered from refractoriness. This can arise from abnormalities in conduction or repolarization or both \[[@B5]\]. Circus reentry requires three prerequisites: (i) conduction velocity (CV) which must be sufficiently slowed so that the tissue ahead of the action potential (AP) wavefront remains excitable, (ii) unidirectional conduction block which must be present to prevent waves from self-extinguishing when they collide, and (iii) an obstacle around which an AP can circulate \[[@B6]\]. This need not be a structural defect but can be a functional core of refractory tissue, which may arise dynamically from ectopic activity \[[@B7]\]. Repolarization abnormalities can result in early or delayed afterdepolarizations (EADs and DADs), which can initiate triggered activity when their magnitudes are sufficiently large to reach the threshold potential for sodium channel reactivation. They can also increase the dispersion of repolarization, promoting unidirectional conduction block and reentry. In diabetes mellitus, arrhythmogenesis can be due to the following mechanisms. Abnormalities in conduction are mediated by myocardial ischaemia \[[@B8]\] or in repolarization \[[@B9], [@B10]\] by ion channel dysfunction, increased adrenergic drive, and calcium overload \[[@B11]\]. These abnormalities are superimposed upon a cardiomyopathy, in which the structural changes also predispose to arrhythmias. Extracardiac abnormalities, for example, neural pathway remodelling, can further promote arrhythmogenesis \[[@B12]\]. Ventricular arrhythmias are thought to underlie sudden cardiac death (SCD) in type 2 diabetic patients and also the "dead-in-bed syndrome" observed in otherwise young healthy adults with type 1 diabetes \[[@B13]\].

3. Abnormal Conduction {#sec3}
======================

CV depends upon sodium channel activation followed by electrotonic spread of the ionic currents via gap junctions, which are electrical coupling pathways located between adjacent cardiomyocytes \[[@B14]\]. Each gap junction is made of two connexons, and each connexon is a hexamer of connexins (Cx). Altered gap junction expression or function can produce conduction abnormalities and in turn predispose to reentrant excitation. Protein kinase C- (PKC-) mediated phosphorylation, a calcium-dependent process, at serine 368 of Cx43, has been linked to reduced gap junction conductance \[[@B15], [@B16]\]. Dephosphorylation of gap junctions results in their uncoupling \[[@B17]\] and lateralization \[[@B18], [@B19]\]. There is consistent evidence demonstrating altered gap junction function or expression in different experimental models of diabetes. Thus, in transgenic mice with cardiac-specific overexpression of peroxisome proliferator-activated receptor *γ* 1 (PPAR*γ*1) modelling human diabetes, reduced Cx43 expression without alterations in CV was observed \[[@B20]\]. This may increase anisotropy and higher likelihood of reentry. In streptozotocin- (STZ-) induced diabetic rats, expression levels of Cx40, 43 and 45 in the SA node, are significantly increased, which were associated with SA conduction delay \[[@B21]\]. This can be explained by increased expression levels of Cx45, which has the lowest unitary conductance and whose expression reduces CV. In both atria and ventricles of the same model, Cx43 phosphorylation was decreased because of reduced PKC*ε* expression \[[@B22]\]; Cx43 was upregulated in the atria, whereas its expression level was unchanged in the ventricles \[[@B23]\]. Furthermore, the lack of insulin signalling can lead to reduced CV of propagating APs.

Myocardial fibrosis is increasingly recognized to be a pathogenic factor in diabetic cardiomyopathy \[[@B24]\]. Fibrosis resulting from fibroblast activation is mediated by growth factors, such as transforming growth factor-*β* \[[@B25]\]. This produces conduction abnormalities via two mechanisms: (i) reduced coupling between cardiomyocytes, leading to increased axial resistance; (ii) increased coupling between fibroblast and cardiomyocyte, increasing membrane capacitance \[[@B26]\]. Both mechanisms lead to a decrease in CV. Cardiac magnetic resonance (CMR) with late gadolinium enhancement is used for the diagnosis and monitoring of cardiomyopathy \[[@B27]--[@B29]\] and is potentially useful for examining fibrosis in diabetic cardiomyopathy.

Hypoglycemic episodes are associated with myocardial ischaemia \[[@B8]\], which may predispose to ventricular arrhythmias by producing conduction defects via the following mechanisms \[[@B14]\]. Ischaemia results in ATP depletion, metabolic switching to anaerobic glycolysis, extracellular H^+^ accumulation, and intracellular Ca^2+^ overload. Cytosolic Ca^2+^ binds to the conserved C2 domain of PKC, thereby activating it \[[@B30]\]. There are several downstream targets of PKC. Firstly, PKC phosphorylates the serine residue at 1505 position of the sodium channel inactivation gate between domains III and IV, which decreases *I* ~Na~ \[[@B31]\]. Secondly, it also phosphorylates connexins (Cx) 43 at serine 368, reducing gap junction conductance \[[@B15], [@B16]\]. Ca^2+^ overload is also associated with dephosphorylation of gap junctions \[[@B32]\], resulting in their uncoupling \[[@B17]\] and lateralization \[[@B18], [@B19]\]. Thus, myocardial ischaemia secondary to hypoglycaemia reduces CV and increases dispersion of conduction, predisposing to reentrant excitation.

4. Abnormal Repolarization {#sec4}
==========================

Action potential repolarization has two phases: (i) early rapid repolarization resulting from the activation of the fast and slow transient outward potassium currents, *I* ~to,f~ and *I* ~to,s~, and (ii) prolonged plateau resulting from a balance between the inward currents mediated by the voltage-gated L-type calcium channel (LTCC, *I* ~Ca,L~) and sodium-calcium exchanger (*I* ~NCX~) and the outward currents mediated by the voltage-gated delayed rectifier potassium channels (*I* ~K~: rapid and slow currents, *I* ~Kr~ and *I* ~Ks~) \[[@B33]\]. There is also contribution from the inward rectifying current (*I* ~K1~). Of these, the human ether-à-go-go-related gene (HERG) K^+^ channel is the major component of delayed rectifier K^+^ current \[[@B34]\].

In diabetes mellitus, prolongations in action potential durations (APDs) are due to several mechanisms. The lack of insulin signalling resulted in electrophysiological remodelling: *I* ~to~ is reduced as a result of reduced expression of Kv4.2 and KChiP2 genes \[[@B35]\]. This current is posttranslationally regulated by a number of different kinases. For example, the p90 ribosomal S6 kinase (p90RSK) is a serine/threonine kinase with N- and C-terminal kinase domains. Reactive oxygen species (ROS), which are raised in diabetes \[[@B36]\], increases the activity of p90RSK and reduced the activity of *I* ~to,f~, *I* ~K,slow~, and *I* ~SS~ channels \[[@B37]\]. Moreover, transgenic mice with cardiac-specific overexpression of peroxisome proliferator-activated receptor *γ* 1 (PPAR*γ*1) showed abnormal lipid accumulation in cardiomyocytes and reduced expression as well as function of *I* ~to,f~ and *I* ~K,slow~\[[@B20]\]. The Rad (Ras associated with diabetes) protein is implicated in diabetes: in its dominant negative mutant, LTCC was upregulated \[[@B38]\]. Together, increased inward currents and decreased outward currents lead to prolonged ventricular repolarization. Conversely, genetic mutations of key ion channel genes causing prolonged ventricular repolarization can also lead to diabetes. For example, mutations in KCNE2 are responsible for long QT syndrome type 5. Whole-transcript transcriptomics demonstrated that KCNE2^−/−^ mice additionally showed diabetes mellitus, hypercholesterolemia, and elevated angiotensin II levels \[[@B39]\]. Hypoglycaemia causes intracellular depletion of ATP in cardiomyocytes and hyperglycaemia increases the production of reactive oxygen species (ROS), both leading to HERG channel dysfunction \[[@B40]\]. K~ATP~ channels are thought to provide a link between cellular energy status and membrane electrophysiology. They are normally inhibited by ATP and activated by ADP. During ischaemia, there are ATP depletion and ADP accumulation, activating *I* ~K,ATP~ and promoting APD shortening \[[@B41]\]. In diabetes, initial APD shortening is also observed but this becomes fully reversed in a time-dependent manner. This failure of APD adaptation, when accompanied by increased adrenergic drive, can engage in steep APD restitution, in turn leading to the production of arrhythmogenic APD alternans \[[@B7]\].

Hypoglycaemia is also associated with another cause of delayed repolarization, hypokalaemia \[[@B42], [@B43]\], which arises from insulin therapy or increased adrenergic drive \[[@B44], [@B45]\]. Hypokalaemia inhibits *I* ~K1~, thereby prolonging APDs and causing L-type Ca^2+^ channel reactivation \[[@B46]\]. This then leads to early afterdepolarizations (EADs) and consequent triggered activity \[[@B47]\]. Hypokalaemia also preferentially prolongs epicardial APDs and leaving endocardial APDs unchanged, increasing the transmural repolarization gradient \[[@B47]\]. In combination with reduced effective refractory periods (ERPs), excitation wavelength (conduction velocity (CV) × ERP) is reduced. Furthermore, increased steepness of APD restitution results in the development of APD alternans \[[@B48]\] and in turn in wavebreak, conduction block, and initiation and maintenance of reentrant activity \[[@B7], [@B49]\].

Hypoglycaemia also increases adrenergic drive with the following proarrhythmic consequences \[[@B51]\]. Firstly, the release of catecholamines leads to abnormal Ca^2+^ cycling and intracellular Ca^2+^ accumulation. This in turn stimulates spontaneous Ca^2+^ release from the sarcoplasmic reticulum, thereby activating three calcium-sensitive currents: the nonselective cationic current, *I* ~NS~, the sodium-calcium exchange current, *I* ~NCX~, and the calcium-activated chloride current, *I* ~Cl,Ca~. Thus, such inward currents observed during phase 4 of the action potential lead to delayed afterdepolarizations (DADs), eliciting triggered activity.

Abnormal Ca^2+^ dynamics have been implicated in diabetes. For example, cardiomyocytes of leptin-deficient ob/ob mice showed reduced amplitudes of Ca^2+^ transients, and insulin elicited extra transients via inositol 1,4,5-trisphosphate (IP~3~) signalling and impaired mitochondrial Ca^2+^ handling \[[@B52]\]. Furthermore, decreases in DAG-mediated nonselective cation currents were associated with reduced TRPC3 expression at the plasma membrane, which increases Ca^2+^ influx \[[@B53]\]. Dysregulation of the type 2 ryanodine receptor (RyR2) has been detected in a STZ-induced diabetes rat model, in which increased frequency of Ca^2+^ sparks with reduced amplitudes was associated with increased sensitivity to Ca^2+^ activation and dyssynchronous Ca^2+^ release \[[@B54], [@B55]\]. Abnormal RyR2 gating mechanism may arise from increased phosphorylation by protein kinase A (PKA, serine 2808) and Ca^2+^/calmodulin-dependent protein kinase II (CaMKII, serine 2808 and serine 2814) \[[@B56]--[@B58]\], as well as oxidation by ROS and reactive carbonyl species (RCS), which are increased in diabetes \[[@B59]--[@B61]\]. Uncontrolled hyperglycaemia can lead to activation of CaMKII and subsequent Ca^2+^ release from the SR \[[@B62]\]. Dyssynchronous Ca^2+^ release can be explained by remodelling of the transverse tubular system, whereby RyR2 become orphaned when they are decoupled from LTCCs \[[@B63]\]. Interestingly, catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by RyR2 mutation, and patients suffering from this condition are also prone to impaired glucose homeostasis and insulin secretion \[[@B64]\]. It would be interesting to determine whether diabetic patients with acquired dysfunction in RyR2 develop bidirectional VT classically associated with CPVT.

Moreover, diabetes mellitus is an independent risk factor for atrial fibrillation, yet the underlying physiological mechanisms are incompletely understood. It may involve ion channel remodelling in the atria. For example, the small conductance Ca^2+^-activated K^+^ (SK) channels contribute to atrial repolarization. SK2 and SK3 isoforms are downregulated, leading to APD prolongation \[[@B65]\]. Normally, SK channels do not play a role in ventricular repolarization. In heart failure, SK currents and ion channel expression can be upregulated and become more sensitive to Ca^2+^ modulation, potentially leading to ventricular arrhythmias \[[@B66]\]. Altered expression of SK channels in the ventricles may play a role in diabetes but this remains to be tested experimentally.

5. Diabetic Cardiomyopathy: Cardiac Electrophysiological and Structural Remodelling with Superimposed Autonomic Dysregulation {#sec5}
=============================================================================================================================

Diabetic cardiomyopathy is characterized by diastolic dysfunction with preserved systolic function, findings that are similarly observed in genetically modified, leptin receptor deficient, diabetic db/db mice on echocardiography \[[@B67], [@B68]\]. Cardiac magnetic resonance imaging is excellent for characterizing structural abnormalities, such as areas of fibrosis by late gadolinium enhancement \[[@B27]--[@B29]\]. Afferent and efferent neural pathways normally regulate inotropic, lusitropic, chronotropic, and dromotropic responses of the heart. In diabetes, these can become dysregulated with impaired baroreceptor control of heart rate \[[@B69]\]. Reduced heart rate variability (HRV) has long been associated with increased mortality \[[@B70]\]. In diabetes, a reduction in HRV was associated with increased incidence of inducible VT by programmed electrical stimulation \[[@B71]\]. Electrophysiological modelling is likely to be an early event, appearing before structural abnormalities. Thus, STZ-induced diabetic rats showed decreases in both maximal transport capacity of SERCA2a and RyR2 conductance, associated with impairment of both inotropic and lusitropic responses in response to adrenergic stimulation \[[@B72]\]. This finding differs from human findings with impaired positive inotropic response with preservation of positive lusitropic effects of beta-adrenoceptor stimulation \[[@B73]\].

Brady-arrhythmias in the form of sinoatrial (SA) and atrioventricular (AV) nodal blocks are seen in diabetes \[[@B74], [@B75]\]. Sinoatrial node (SAN) dysfunction was demonstrated in db/db mice, which demonstrated prolonged SAN recovery time \[[@B67]\]. These mice showed no significant differences in conduction intervals and wave amplitudes compared to control mice. By contrast, sinus tachycardia at rest has been associated with excessive mortality in diabetic patients \[[@B76]\]. This may be related to autonomic dysregulation, with increased adrenergic drive with or without impairment of parasympathetic response. Thus, in Akita diabetic mice, the SA node is less responsive to acetylcholine because of a reduction in acetylcholine-activated K^+^ current (*I* ~K,ACh~), which is due to altered phosphoinositide 3-kinase (PI3K) signalling \[[@B77]\].

Some aspects of altered cardiac electrophysiology in diabetes do not arise from abnormalities in the heart itself, but instead from neural pathways innervating it. Thus, in STZ-induced diabetic mice, both baroreflex tachycardia and bradycardia were blunted. This was associated with remodelling of the baroreceptor circuitry, in which the sizes of cardiac ganglia and ganglionic principal neurons were decreased. In a different model, the OVE26 diabetic mice showed neural degeneration in the nucleus ambiguus, which is one of the two brainstem nuclei innervating the cardiac ganglia \[[@B78]\]. Furthermore, altered balance between chemoattractants (e.g., nerve growth factor) and chemorepellants (Sema3a) leads to disruptions in innervation pattern, precipitating arrhythmias, and sudden death \[[@B79]\].

6. Clinical Relevance and Future Therapies {#sec6}
==========================================

Traditional agents used for treatment of diabetes or associated comorbidities such as hypertension have been shown to exert cardiac protective effects in diabetes by previously unknown mechanisms. Thus, for example, in the STZ-induced diabetic rat model, *I* ~to~ and *I* ~SS~ are downregulated and the cardiac renin-angiotensin system is activated. Experimental evidence has demonstrated augmentation of both currents by the antihypertensive angiotensin II receptor blockers \[[@B80]\]. The ACE inhibitor enalapril \[[@B81]\] and angiotensin II receptor blocker losartan \[[@B82]\] were also shown to exert antifibrotic effects in hypertension and may have similar cardioprotective effects in diabetes by similar mechanisms. The antifibrotic hormone relaxin could be delivered using adenoviruses \[[@B83]\] and may reverse fibrosis in diabetic cardiomyopathy. Ion channels represent an attractive target for managing arrhythmic complications of diabetes mellitus ([Table 1](#tab1){ref-type="table"}). Novel agents such as late sodium current blockers \[[@B84]\] and gap junction openers \[[@B49]\] can be used to reduce abnormal repolarization and conduction, respectively. Alternatively, gap junction inhibitors can prolong effective refractory periods and exert antiarrhythmic effects \[[@B47]\]. Paradoxically, mild gap junction uncoupling could improve the safety margin of conduction and increase CV, removing unidirectional conduction blocks and converting these into bilateral conduction. Their use in diabetes warrants future exploration. Ryanodine receptor stabilizers have the potential to normalize Ca^2+^ handling in diabetes, which remains to be tested \[[@B86]\]. However, caution must be exercised to screen for deleterious, ventricular proarrhythmic effects. K~ATP~ channels play a role in not only insulin secretion but also cardiac repolarization. Whilst the K~ATP~ channel activators have been used to increase insulin release, they have the potential to cause life-threatening ventricular arrhythmias, especially in a subset of patients with ischaemic complications. In diabetes, mitochondrial K~ATP~ channel activation in cardiomyocytes by dioxide led to impaired APD adaptation, which promoted the occurrence of VT \[[@B87]\]. Future efforts therefore require an integrated approach by computation modelling, where effects of drugs on complex spatiotemporal properties of cardiac dynamics are tested to reduce the likelihood of life-threatening side effects. Animal models will be useful for studying arrhythmogenic mechanisms and provide a platform for assessing the efficacy of pharmacological therapy with translational applications \[[@B88]--[@B90]\].
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  -------------------------------------------------------------------------------------------------------------------------------------------
  Molecular target                 Mechanism of action                                                                           References
  -------------------------------- --------------------------------------------------------------------------------------------- ------------
  Gap junction inhibitors          Increase refractory period\                                                                   \[[@B47]\]
                                   Improve conduction                                                                            

                                                                                                                                 

  Gap junction openers             Increase conduction velocity and decrease heterogeneity in repolarization or refractoriness   \[[@B49]\]

                                                                                                                                 

  Late sodium channel blockers     Inhibit afterdepolarizations                                                                  \[[@B84]\]

                                                                                                                                 

  Ryanodine receptor stabilizers   Decrease heterogeneity in Ca^2+^ transients and inhibit afterdepolarizations                  \[[@B86]\]

                                                                                                                                 

  Antifibrotic agents              Reduce cardiac fibrosis                                                                       \[[@B83]\]
  -------------------------------------------------------------------------------------------------------------------------------------------
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